Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Dec 2018
Price : $35 *
At a glance
- Drugs Rifapentine (Primary) ; Isoniazid
- Indications Tuberculosis
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 30 Oct 2015 Planned number of patients changed from 363 to 322, according to ClinicalTrials.gov record.